US Pharma MarketingEurope's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Less than a month after an FDA advisory committee voted 6-3 Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.
Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.
Source: FiercePharma